Michigan is currently home to 2248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Breast Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
Recruiting
Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/27/2022
Locations: Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan
Conditions: Liver Metastases, Non-small Cell Lung Cancer
Mechanistic Study of Ocrevus
Recruiting
The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/27/2022
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Multiple Sclerosis
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
Recruiting
The primary study objective of the NASA registry is to evaluate the 12-month incidence of target vessel failure (TVF) in patients who present with saphenous vein graft (SVG) lesions and undergo percutaneous coronary intervention (PCI) of the corresponding native coronary artery.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/20/2022
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Target Vessel Failure in Saphenous Vein Grafts, Percutaneous Coronary Intervention
Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting
Recruiting
The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.
Gender:
All
Ages:
Between 19 years and 80 years
Trial Updated:
06/16/2022
Locations: Ascension, St. John Hospital, Detroit, Michigan
Conditions: Carotid Artery Stenosis
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Recruiting
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/15/2022
Locations: Ascension Providence Rochester Hospital, Rochester, Michigan
Conditions: Metastatic Cancer
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2022
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
Recruiting
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/03/2022
Locations: Wayne State University, Detroit, Michigan
Conditions: Multiple Sclerosis, Relapsing-Remitting
Digital Design for Maxillofacial Prosthetics
Recruiting
This study will use a 3D scanner to print a 3D model or mold for each patient's prosthesis. The goal of this study to provide patients with a new, faster method of imaging and creating prostheses that preserves the quality of the current method while reducing time spent by both the patient and providers. Patients that are eligible will have a non-invasive 3D scanner (Artec Space Spider) to image the indicated areas of their head and face to help create their new prosthesis. Patients will come in... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
05/31/2022
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Prosthetic Treatment, Craniofacial Abnormalities, Maxillofacial Abnormalities
Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients
Recruiting
Objective: Test the ability of vibration to produce physiologic, biochemical, and anatomic changes consistent with exercise that would help prevent the development of muscle weakness that occurs when patients are immobile for long periods of time.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2022
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Critically Ill, Post Intensive Care Syndrome
Guiding Good Choices for Health
Recruiting
This study evaluates the feasibility and effectiveness of implementing Guiding Good Choices (GGC), an anticipatory guidance curriculum for parents of early adolescents, in three large, integrated healthcare systems. By "parents," the study team is referring here and throughout this protocol to those adults who are the primary caregivers of children, irrespective of their biological relationship to the child. In prior community trials, GGC has been shown to prevent adolescent substance use (alcoh... Read More
Gender:
All
Ages:
Between 11 years and 12 years
Trial Updated:
05/19/2022
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Adolescent Substance Use